NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IOVA stock has increased by 8.7% and is now trading at $32.16. View which stocks have been mosted impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iovance Biotherapeutics.

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Iovance Biotherapeutics.

Iovance Biotherapeutics Inc (NASDAQ:IOVA) released its quarterly earnings data on Tuesday, February, 25th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.42) by $0.08. View Iovance Biotherapeutics' earnings history.

14 Wall Street analysts have issued 1-year price objectives for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $45.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $34.62 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price. View analysts' price targets for Iovance Biotherapeutics.

Media stories about IOVA stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Iovance Biotherapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutIovance Biotherapeutics.

Iovance Biotherapeutics saw a drop in short interest in March. As of March 13th, there was short interest totaling 12,825,400 shares, a drop of 11.9% from the February 27th total of 14,560,000 shares. Based on an average trading volume of 2,203,500 shares, the days-to-cover ratio is presently 5.8 days. Currently, 11.1% of the company's stock are short sold. View Iovance Biotherapeutics' Current Options Chain.

Some companies that are related to Iovance Biotherapeutics include NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Qiagen (QGEN), Moderna (MRNA), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), Adaptive Biotechnologies (ADPT) and Audentes Therapeutics (BOLD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Micron Technology (MU), Bristol-Myers Squibb (BMY) and Heron Therapeutics (HRTX).

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Iovance Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (7.46%), Perceptive Advisors LLC (7.46%), Farallon Capital Management LLC (4.95%), Franklin Resources Inc. (4.33%), Franklin Resources Inc. (4.34%) and State Street Corp (3.43%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends for Iovance Biotherapeutics.

IOVA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Franklin Resources Inc., Franklin Resources Inc., Broadfin Capital LLC, State Street Corp, Rafferty Asset Management LLC, and Nuveen Asset Management LLC. View insider buying and selling activity for Iovance Biotherapeutics.

IOVA stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Norges Bank, Fairmount Funds Management LLC, Artisan Partners Limited Partnership, Eagle Asset Management Inc., Rothschild & Co. Asset Management US Inc., Crawford Lake Capital Management LLC, and Farallon Capital Management LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak, and Wayne P Rothbaum. View insider buying and selling activity for Iovance Biotherapeutics.

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IOVA stock can currently be purchased for approximately $32.16.

Iovance Biotherapeutics has a market capitalization of $4.07 billion. The biotechnology company earns $-197,560,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe. View additional information about Iovance Biotherapeutics.

The official website for Iovance Biotherapeutics is http://www.iovance.com/.

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]